Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05050799 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

US Post-Market Surveillance Study of the Surfacer System

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 9v11
  2. Primary completion date: Feb 10, 2026 to Dec 15, 2026
    • Study completion date: Feb 28, 2026 to Dec 15, 2026
    • Site contacts updated at 4 of 6 sites
    v10
  3. Primary completion date: Feb 10, 2025 to Feb 10, 2026
    • Study sites: 5 to 6
    • Study completion date: Feb 28, 2025 to Feb 28, 2026
    v9
  4. Primary completion date: Aug 10, 2024 to Feb 10, 2025
    • Study completion date: Aug 31, 2024 to Feb 28, 2025
    v8
  5. Study sites: 4 to 5v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 4v6
  2. Trial status: Active, Not Recruiting to Recruiting
    • Study sites revised (3)
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Primary completion date: Aug 10, 2023 to Aug 10, 2024v3 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 3
    • Study completion date: Oct 1, 2023 to Aug 31, 2024
    • Eligibility criteria expanded, about 20 words
    • Study description expanded, about 2 words
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 20, 2022 to Feb 8, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Trial Details
NCT Number NCT05050799
Lead Sponsor Merit Medical Systems, Inc.
Conditions
(from sponsor)		 Venous Disease
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov